Kalaris Therapeutics
KLRS
84 hedge funds and large institutions have $192M invested in Kalaris Therapeutics in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 15 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 18
36% more call options, than puts
Call options by funds: $110K | Put options by funds: $81K
0.01% more ownership
Funds ownership: 1.74% → 1.75% (+0.01%)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 85 → 84 (-1)
34% less capital invested
Capital invested by funds: $294M → $192M (-$101M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.6M |
| 2 |
BlackRock
New York
|
+$1.1M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$1.07M |
| 4 |
Renaissance Technologies
New York
|
+$908K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$574K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$2.35M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.77M |
| 3 |
Morgan Stanley
New York
|
-$1.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.27M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$263K |
KLRS Hedge Fund Activity: Q4 2022 in Review
84 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2022, worth a combined $192M — down 34% from $294M a quarter earlier.
Fund positioning in KLRS was balanced in Q4 2022: 15 funds opened new positions, 15 closed out, 35 added to existing stakes and 18 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $2.6M. The largest seller was Alkeon Capital Management, cutting an estimated $2.35M.
- 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2022, down from 85 in Q3 2022.
- Funds reported $192M of Kalaris Therapeutics stock for Q4 2022, down 34% quarter-over-quarter.
- 15 funds opened new Kalaris Therapeutics positions in Q4 2022 and 15 closed out, a net change of 0 holders.
- The largest Kalaris Therapeutics buyer in Q4 2022 was JP Morgan Chase, an estimated $2.6M added.
- The largest Kalaris Therapeutics seller in Q4 2022 was Alkeon Capital Management, an estimated $2.35M sold.
Based on aggregated 13F filings for Q4 2022.